Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Antipsychotic Dosing in Schizophrenia
NCT04478838Phase 4Recruiting
- Sponsor
- Center for Addiction and Mental Health
- Start
- Jun 2022
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of risperidone, olanzapine and paliperidone in schizophrenia (2 arms), sponsored by Center for Addiction and Mental Health. Primary endpoint: Brief Psychiatric Rating Scale - Expanded at 52 weeks. Started Jun 2022; status: recruiting.
02
Drugs
risperidoneolanzapinepaliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04478838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478838.